Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) General Counsel Jeff Cislini sold 1,500 shares of the stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $21.70, for a total value of $32,550.00. Following the transaction, the general counsel now owns 38,513 shares in the company, valued at $835,732.10. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Jeff Cislini also recently made the following trade(s):
- On Thursday, September 28th, Jeff Cislini sold 2,000 shares of Revolution Medicines stock. The stock was sold at an average price of $28.20, for a total value of $56,400.00.
- On Monday, September 18th, Jeff Cislini sold 1,214 shares of Revolution Medicines stock. The stock was sold at an average price of $31.31, for a total value of $38,010.34.
Revolution Medicines Stock Performance
Shares of RVMD traded up $0.40 on Monday, reaching $21.73. The stock had a trading volume of 1,381,309 shares, compared to its average volume of 1,496,093. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -6.67 and a beta of 1.47. The company has a 50-day simple moving average of $25.30 and a 200-day simple moving average of $26.90. Revolution Medicines, Inc. has a 12-month low of $15.44 and a 12-month high of $35.60.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on RVMD shares. JPMorgan Chase & Co. reduced their price target on Revolution Medicines from $47.00 to $39.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 7th. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of Revolution Medicines in a report on Tuesday, November 7th. Stifel Nicolaus increased their price objective on Revolution Medicines from $37.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, September 21st. Oppenheimer increased their price objective on Revolution Medicines from $40.00 to $43.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Finally, Raymond James initiated coverage on Revolution Medicines in a report on Thursday. They issued an “outperform” rating and a $30.00 price objective for the company. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.50.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Voya Investment Management LLC increased its position in Revolution Medicines by 1.3% during the 4th quarter. Voya Investment Management LLC now owns 28,543 shares of the company’s stock valued at $680,000 after buying an additional 370 shares in the last quarter. Legal & General Group Plc increased its position in Revolution Medicines by 1.0% during the 2nd quarter. Legal & General Group Plc now owns 44,308 shares of the company’s stock valued at $863,000 after buying an additional 449 shares in the last quarter. State of Wisconsin Investment Board increased its position in Revolution Medicines by 0.8% during the 4th quarter. State of Wisconsin Investment Board now owns 61,555 shares of the company’s stock valued at $1,466,000 after buying an additional 464 shares in the last quarter. US Bancorp DE increased its position in Revolution Medicines by 68.1% during the 2nd quarter. US Bancorp DE now owns 1,575 shares of the company’s stock valued at $42,000 after buying an additional 638 shares in the last quarter. Finally, Amalgamated Bank increased its holdings in shares of Revolution Medicines by 5.3% in the 3rd quarter. Amalgamated Bank now owns 15,587 shares of the company’s stock worth $431,000 after purchasing an additional 787 shares in the last quarter.
Revolution Medicines Company Profile
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors.
- Five stocks we like better than Revolution Medicines
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- The most upgraded stocks in November have two things in common
- How to Calculate Return on Investment (ROI)
- Monday.com rocked earnings like it’s the weekend
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.